AUTHORS
Murali Janakiram, MBBS, Ni-Chun Tsai2, Michael Rosenzweig, MD3, L. Elizabeth Elizabeth Budde, MD PhD4, Scott R Goldsmith, MD5, Nitya Nathwani, MD6, Jonathan Keats, PhD7, Yan Wang8, James Sanchez9, Sarah Lee Jr10, Lisa X. Lee, M.D.11, Joycelynne Palmer, PhD12, Arnab Chowdhury, MS13, Myo Htut, MD14, Stephen J. Forman, MD15, Amrita Krishnan, MD, FACP16
AFFILIATIONS
1 City of Hope National Medical Center, Duarte, California, United States
2 City of Hope National Medical Center, Duarte, California, United States
3 City of Hope National Medical Center, Duarte, California, United States
4 City of Hope National Medical Center, Duarte, California, United States
5 City of Hope National Medical Center, Duarte, California, United States
6 City of Hope National Medical Center, Duarte, California, United States
7 City of Hope National Medical Center, Duarte, California, United States
8 City of Hope National Medical Center, Duarte, California, United States
9 City of Hope National Medical Center, Duarte, California, United States
10 City of Hope National Medical Center, Duarte, California, United States
11 City of Hope National Medical Center, Duarte, California, United States
12 City of Hope National Medical Center, Duarte, California, United States
13 City of Hope National Medical Center, Duarte, California, United States
14 City of Hope National Medical Center, Duarte, California, United States
15 City of Hope National Medical Center, Duarte, California, United States
16 City of Hope National Medical Center, Duarte, California, United States
ABSTRACT
Background: Ciltacabtagene autoleucel (cilta-cel) has transformed outcomes in relapsed/refractory multiple myeloma (RRMM), but cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) have historically mandated inpatient administration, limiting access and increasing healthcare resource utilization (HCRU). A prior analysis demonstrated that outpatient delivery reduced HCRU, but was limited by a small outpatient cohort (n=37), restriction to 1–3 prior lines of therapy, and reliance on imputed cost outcomes.
Methods: We performed a retrospective, single-center review of consecutive adult patients with RRMM receiving outpatient cilta-cel between August 2022 and March 2026. The protocol comprised of outpatient fludarabine/cyclophosphamide lymphodepletion on days −5 to −3, infusion on day +1, daily outpatient visits through day +14, then weekly through day +28. Eligibility required continuous caregiver support and proximity within 30 minutes of the hospital; there was no upper age limit. Patients requiring dialysis or continuous cardiac telemetry were excluded. Remote monitoring was not employed; patients were educated to self-report fever and call the triage line. Baseline characteristics, prior therapies, HCRU, admissions, and toxicities (graded per ASTCT criteria) were collected. All patients had a minimum planned 100-day follow-up for response, progression-free survival (PFS), and non-relapse mortality (NRM).
Results: Of 222 patients (median age 64 yrs [range 33–79]; 23.9% aged ≥70), median prior therapy were 5 (range 0–14) and 61.7% were triple-class exposed. Median KPS was 90; HCT-CI ≥1-53.6% and CAR-HEAMTOTOX 0=21,6%, 1=22.5%, 2=14.6%. CRS occurred in 73.9% (gr 1, 62.6%; gr ≥2, 11.3%) at a median onset of day 6 (range 0–13). ICANS occurred in 5.9% (grade ≥3, 0.9%).
A total of 22.1% of patients remained outpatient throughout the first 30 days. Among the 77.9% admitted, the median time to 1st admission was 6 days (range 0–16), median length of stay was 3 days (range 1–81), and ICU-level care was required in only 0.9%. Reasons for admission were fever/CRS/immune effector cell-related complications (83.8%), disease-related (11.6%), other (2.9%), and infection (1.7%).
Day +100 overall response rate was 75.2% (≥VGPR 39.2%; PR 36.0%; 15.3% not evaluable). Among 152 patients with survival follow-up (median 12.1 months [range 2.1–36.1]), 30-day NRM was 0% and 100-day NRM was 0.7% (95% CI: 0.1–3.4). PFS was 91.8% (95% CI: 85.7–95.4) at 6 months and 84.6% (95% CI: 76.5–90.1) at 12 months. In an internal cost analysis (direct costs excluding drug acquisition), outpatient care was associated with 2.8-fold lower costs and less HCRU than inpatient care from day +1 to day +14.
Conclusion: In the largest reported outpatient cilta-cel experience to date, a structured daily-monitoring model with admission reserved for fever or constitutional symptoms was safe and effective with a 0% 30-day NRM, encouraging PFS, and substantially lower cost and HCRU than inpatient care. Patient education and caregiver support-maintained safety without the need for remote monitoring. Safety and efficacy were preserved in patients aged ≥70 years (23.9%), supporting outpatient CAR-T as a feasible, lower-cost strategy.
DISCLOSURES
Murali Janakiram, MBBS: Celgene - Research Funding; Fate Therapeutics - Research Funding; BMS, Legend - Consultancy (Includes expert testimony); Jansen - Consultancy (Includes expert testimony); Fate Therapeutics - Consultancy (Includes expert testimony); Celgene - Consultancy (Includes expert testimony)